LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VYGR
Voyager Therapeutics, Inc.
There isn't enough reported data to score VYGR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VYGR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
VYGR's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VYGR PE Valuation
VYGR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VYGR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect VYGR's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over VYGR on earnings quality, reporting a profit while its opponent remains loss making.
VYGR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.74 | +$0.42 |
| Q2 2026 | -$1.81 | +$0.04 |
| Q1 2026 | -$1.98 | -$0.52 |
| Q4 2025 | -$2.04 | -$0.91 |
| Q3 2025 | -$2.16 | -466% |
| Q2 2025 | -$1.85 | -1256% |
| Q1 2025 | -$1.46 | -$1.29 |
| Q4 2024 | -$1.13 | -138% |
VYGR is still losing money, but less than at its worst: $1.74 per share over the past year, against $2.45 at its worst in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VYGR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VYGR on profitability, with a higher operating margin.
VYGR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | -70% |
| Q2 2026 | $3.2M | -39% |
| Q1 2026 | $2.6M | -60% |
| Q4 2025 | $15.3M | +144% |
| Q3 2025 | $13.4M | -46% |
| Q2 2025 | $5.2M | -82% |
| Q1 2025 | $6.5M | -67% |
| Q4 2024 | $6.3M | -93% |
VYGR's revenue has slid since its 2023 peak: $4M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -658% | -429 points |
| Q2 2026 | -834% | -130 points |
| Q1 2026 | -1167% | -631 points |
| Q4 2025 | -195% | +415 points |
| Q3 2025 | -229% | -173 points |
| Q2 2025 | -704% | -654 points |
| Q1 2025 | -536% | -453 points |
| Q4 2024 | -610% | -670 points |
VYGR's operating margin was −658% last quarter, down 429 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VYGR on cash generation, producing positive trailing cash flow while its opponent burns cash.
VYGR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.7M | +$11.6M |
| Q2 2026 | -$25.8M | +$8.5M |
| Q1 2026 | -$33.4M | +$5.1M |
| Q4 2025 | -$30.9M | -$16.2M |
| Q3 2025 | -$31.3M | -$3M |
| Q2 2025 | -$34.4M | -$1.8M |
| Q1 2025 | -$38.6M | -168% |
| Q4 2024 | -$14.7M | +$9.8M |
VYGR has burned cash in almost every quarter: −$110M over the past year, against −$119M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VYGR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VYGR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +1.3M shares |
| 1 year | +5.1% | +3M shares |
| 3 years | +41% | +18M shares |
| 5 years | +64% | +24M shares |
| Available history | +72% | +25.9M shares |
VYGR has 62M diluted shares, up 5.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VYGR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -8.0x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -1.4x | Net Cash |
| Q2 2023 | -2.6x | Net Cash |
| Q1 2023 | -2.7x | Net Cash |
| Q2 2021 | -10.6x | Net Cash |
| Q1 2021 | -3.9x | Net Cash |
| Q4 2020 | -3.4x | Net Cash |
VYGR has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VYGR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.9 | Oversold |
| Stochastic | 4.6 | Oversold |
VYGR's weekly RSI is 27 (oversold) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VYGR PE vs Healthcare Sector
| Metric | VYGR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VYGR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VYGR on trend strength, trading above more of its moving averages.
VYGR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.06 | 17% below |
| 20 week MA | $2.81 | 40% below |
| 50 week MA | $3.45 | 51% below |
| 100 week MA | $3.74 | 55% below |
| 200 week MA | $5.97 | 72% below |
VYGR is in a downtrend: it's below all five of its weekly moving averages, and 72% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VYGR on returns for 2026, with the stronger performance.
VYGR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.9 | $7.98 | -43% |
| 2021 | $7.98 | $2.93 | -63% |
| 2022 | $2.93 | $5.56 | +90% |
| 2023 | $5.56 | $8.44 | +52% |
| 2024 | $8.44 | $5.74 | -32% |
| 2025 | $5.74 | $4.08 | -29% |
| 2026 YTD | $4.08 | $1.70 | -58% |
VYGR has finished lower in four of the last six years. It's down 58% so far in 2026.